Physician

Sujatha Yellinedi, M.D.

According to 2025 Medicare claims, Sujatha Yellinedi, M.D. (NPI: 1265406607) practices medical oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Prince George, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23805-0002.

Yellinedi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 519 traditional Medicare patients, billed 64,697 HCPCS/CPT codes, and received $1,144,517 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 943 prescription claims across 174 beneficiaries totaling $1,114,577 in drug costs, led by Imbruvica (Ibrutinib). 2019 DME data shows 14 claims. Open Payments data shows 78 records totaling $1,708. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $261,685 to $1,114,577. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	442	63,581	$779,985
2016	503	51,547	$763,703
2017	731	93,712	$1,293,866
2018	722	129,079	$1,082,803
2019	698	136,408	$1,261,467
2020	693	114,045	$1,434,677
2021	587	88,830	$1,027,591
2022	582	100,657	$1,145,433
2023	559	88,392	$1,049,169
2024	519	64,697	$1,144,517

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	119	607	$261,685
2016	127	645	$424,978
2017	137	920	$806,746
2018	147	997	$1,213,982
2019	150	970	$1,118,939
2020	152	1,056	$1,621,230
2021	150	982	$1,433,683
2022	158	928	$1,440,016
2023	139	831	$1,219,099
2024	174	943	$1,114,577

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	73	$4,854
2016	N/R	16	$610
2017	N/R	22	$4,645
2018	N/R	11	$716
2019	N/R	14	$3,150
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	72	237	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	258	891	$92
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	74	187	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	89	122	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	172	255	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	25	700	$410,180
Lenalidomide	Lenalidomide	20	560	$300,632
Xarelto	Rivaroxaban	107	4,005	$72,859
Eliquis	Apixaban	89	3,224	$61,471
Tamoxifen Citrate	Tamoxifen Citrate	62	3,345	$1,520

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$1,708	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sujatha Yellinedi, M.D.?

Tedicare shows public-source Medicare data for Sujatha Yellinedi, M.D. (NPI 1265406607), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sujatha Yellinedi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sujatha Yellinedi, M.D.?

Sujatha Yellinedi, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Sujatha Yellinedi, M.D. have Open Payments data?

Sujatha Yellinedi, M.D. has 78 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.